Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Pallmann

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
BMC Medicine|November 17, 2018
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive designMunyaradzi Dimairo, Elizabeth Coates, Philip Pallmann, et al.
BMJ Open|June 13, 2022
PROcalcitonin and NEWS2 evaluation for Timely identification of sepsis and Optimal use of antibiotics in the emergency department (PRONTO): protocol for a multicentre, open-label, randomised controlled trialJoanne Euden, Emma Thomas-Jones, Stephen Aston, et al.
Trials|June 18, 2020
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
BMJ (Clinical Research Ed.)|June 20, 2020
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
BMC Medicine|October 2, 2025
Practical guidance for conducting high-quality and rapid interim analyses in adaptive clinical trialsHelen Mossop, Zoë Walmsley, Nina Wilson, et al.
BMC Medicine|October 26, 2021
Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials projectNina Wilson, Katie Biggs, Sarah Bowden, et al.
The Lancet. Child & Adolescent Health|January 11, 2025
Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH): a pragmatic, multicentre, open-label, two-arm, individually randomised, controlled trialCherry-Ann Waldron, Philip Pallmann, Simon Schoenbuchner, et al.
Trials|August 23, 2024
MulTI-domain self-management in older People wiTh OstEoarthritis and multi-morbidities: protocol for the TIPTOE randomised controlled trialRachel Deere, Philip Pallmann, Victoria Shepherd, et al.
Health Technology Assessment (Winchester, England)|May 19, 2025
Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCTCherry-Ann Waldron, Philip Pallmann, Simon Schoenbuchner, et al.
Methods and Protocols|December 22, 2022
Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational StudyJoanne Euden, Philip Pallmann, Detelina Grozeva, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
BMC Medicine|November 17, 2018
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive designMunyaradzi Dimairo, Elizabeth Coates, Philip Pallmann, et al.
BMJ Open|June 13, 2022
PROcalcitonin and NEWS2 evaluation for Timely identification of sepsis and Optimal use of antibiotics in the emergency department (PRONTO): protocol for a multicentre, open-label, randomised controlled trialJoanne Euden, Emma Thomas-Jones, Stephen Aston, et al.
Trials|June 18, 2020
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
BMJ (Clinical Research Ed.)|June 20, 2020
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
BMC Medicine|October 2, 2025
Practical guidance for conducting high-quality and rapid interim analyses in adaptive clinical trialsHelen Mossop, Zoë Walmsley, Nina Wilson, et al.
BMC Medicine|October 26, 2021
Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials projectNina Wilson, Katie Biggs, Sarah Bowden, et al.
The Lancet. Child & Adolescent Health|January 11, 2025
Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH): a pragmatic, multicentre, open-label, two-arm, individually randomised, controlled trialCherry-Ann Waldron, Philip Pallmann, Simon Schoenbuchner, et al.
Trials|August 23, 2024
MulTI-domain self-management in older People wiTh OstEoarthritis and multi-morbidities: protocol for the TIPTOE randomised controlled trialRachel Deere, Philip Pallmann, Victoria Shepherd, et al.
Health Technology Assessment (Winchester, England)|May 19, 2025
Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCTCherry-Ann Waldron, Philip Pallmann, Simon Schoenbuchner, et al.
Methods and Protocols|December 22, 2022
Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational StudyJoanne Euden, Philip Pallmann, Detelina Grozeva, et al.
Pageof 8